Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All News and Research Articles

New SAMHSA smartphone app provides doctors instant access to resources for medication assisted treatment (MAT).
Interview with Don L. Goldenberg, MD, FACP A viable new class of medications--non-tumor necrosis factor-a--offer physicians an alternative to the currently preferred Tumor Necrosis Factor (TNF) -a drugs, according to findings reported in JAMA.1
The US Food and Drug Administration (FDA) has approved BurstDR device, a new form of spinal cord stimulation (SCS) with evidence of superior clinical benefits over traditional SCS therapy in the treatment of chronic pain.
FDA clears new Ahead 300 device for assessing traumatic brain injury.
The US Food and Drug Administration (FDA) has approved Amjevita (adalimumab-atto), a biosimilar to the popular immunosuppressant Humira (AbbVie Inc.). Amjevita is the fourth biosimilar to be approved by the FDA, as a new wave of biosimilars begin to make their way into the pharmaceutical market.
FDA launches new online resource for clinicians prescribing opioid medications called Search and Rescue. Goal is to reduce misuse and abuse.
Yoga, acupuncture, and tai chi, all found effective for the treamtment of common pain conditions.
FDA approves etanercept-szzs or Erelzi, a tumor necrosis factor biosimilar to etanercept or Enbrel.
DEA denies petitions to reclassify marijuana. Agency notes concerns over safety and addiction, but will not interfere with current states that have legalized marijuana.
New study shows most opioid-naive patients at 1 year follow-up were able to get off their post-operative opioid medications.
New study in the New England Journal of Medicine shows soldiers with sickle cell trait at increased risk of exertional rhabdomyolysis.
New study reveals terminal patients taking methylnaltrexone survive longer, which may reveal new insights about cancer.
New literature review finds generic versions of biologics, or biosimilars, are just as safe and effective as brand name drugs.
New research suggests moderate to severe pain is a risk factor for opioid use disorder.
New literature review finds A118G genetic mutation linked with reduced opioid efficacy.